Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-08-30
2005-08-30
Priebe, Scott D. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A, C435S455000, C435S456000, C435S320100
Reexamination Certificate
active
06936243
ABSTRACT:
The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5693531 (1997-12-01), Chiorini et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 6268213 (2001-07-01), Samulski et al.
patent: 2001/0051611 (2001-12-01), Srivastava et al.
patent: WO 9809524 (1998-12-01), None
Chuah et al., “Gene Therapy for Hemophilia”, J of Gene Medicine 3:3-20, 2001.
Wang et al., “Sustained Expression . . . in Liver”, Mol Ther. 1:154-158, 2000.
Chao et al., “Sustained Expression . . . a Parvovirus-based Vector”, Blood 95:1594-1599, 2000.
Kay et al., “Evidence for . . . with an AAV Vector”, Nat Genet 24:257-261, 2000.
Koeberl et al., “Persistent. Therapeutically . . . Virus Vectors”, Hum Gene Ther 10:2133-2140, 1999.
Liu et al., “Transduction . . . virus”, J Interf Cytokine Res 1:21-30, 2000 (Abstract).
Gene Therapy(1995) 2, 29-37, Flotte et al. “An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.”
Human Gene Therapy,vol. 5, pp. 793-801 (1994). Kotin, “Prospects for the Use of Aden-Associated Virus as a Vector for Human Gene Therapy.”
Orkin et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, issued by the U.S. National Institutes of Health. (1995).
Journal of Virology.vol. 70, No. 1, pp. 520-532 (1996). Fisher et al. “Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis.”
Human Gene Therapy.vol. 8, pp. 125-135 (1997). Chen et al. “Comparison of Retroviral and Adeno-Associated Viral Vectors Designed to Express Human Clotting Factor IX.”
Cas. Lek. Ces.vol. 134, No. 19, pp. 625-629 (1995), Sokol and Prchal “Human Genome—Chromsome No. 19”.
Human Gene Therapy.vol. 7, pp. 463-470 (1996), Su et al. Selective Killing of AFP-Positive Hepatocellular Carcinoma Cells by Adeno-Associated Virus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene.
Journal of Virology.vol. 70, No. 3, pp. 1668-1677 (1996). Wang et al. “Rescue and Replication of Adeno-Associated Virus Type 2 as well as Vector DNA Sequences from Recombinant Plasmids Containing Deletions in the Viral Inverted Terminal Repeats: Selective Encapsidation of Viral Genomes in Progeny Virions.”
Journal of Molecular Biology.vol. 250, pp. 573-580 (1995). Wang et al. “Rescue and Replication Signals of the Adeno-Associated Virus 2 Genome.”
Blood.vol. 86(10 Suppl. 1): p. 240a (1995) Ponnazhagen et al. “Adeno-Associated Virus 2-Mediated Gene Transfer and Expression in Murine Hematopoietic Progenitor Cells.”
Proc. Natl. Acad. Sci. USA.vol. 94, pp. 1426-1431 (1997) Koeberl et al. “Persistent Expression of Human Clotting Factor IX from Mouse Liver after Intravenous Injection of Adeno-Associated Virus Vecotrs.”
Am. J. of Human Genetics.vol. 57, Suppl. 4, p. A43 (1995) Koeberl et al. “Transduction of Hepatocytes in vivo with Adeno-Associated Virus Vectors as a Model for Hepatic Gene Therapy.”
Human Gene Therapy.vol. 7 pp. 1781-1790 (1996) Ross et al. “Gene Therapy in the United States: A Five Year Status Report.”
Proc. Natl. Acad. Sci.vol. 91 pp. 8915-8919 Russell et al. “Adeno-associated virus vectors preferentially transduce cells in S phase.”
Cohen Lawrence K.
Danos Olivier
Kay Mark A.
Snyder Richard O.
Thompson Arthur R.
Cell Genesys Inc.
Judge Linda R.
Kelber Steven B.
Piper Rudnick LLP
Priebe Scott D.
LandOfFree
Adeno-associated viral vector-mediated delivery of DNA to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adeno-associated viral vector-mediated delivery of DNA to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adeno-associated viral vector-mediated delivery of DNA to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456175